Literature DB >> 23633544

Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia.

Anna L Godfrey1, Edwin Chen, Francesca Pagano, Yvonne Silber, Peter J Campbell, Anthony R Green.   

Abstract

Subclones homozygous for JAK2V617F are more common and larger in patients with polycythemia vera compared to essential thrombocythemia, but their role in determining phenotype remains unclear. We genotyped 4564 erythroid colonies from 59 patients with polycythemia vera or essential thrombocythemia to investigate whether the proportion of JAK2V617F -homozygous precursors, compared to heterozygous precursors, is associated with clinical or demographic features. In polycythemia vera, a higher proportion of homozygous-mutant precursors was associated with more extreme blood counts at diagnosis, consistent with a causal role for homozygosity in polycythemia vera pathogenesis. Larger numbers of homozygous-mutant colonies were associated with older age, and with male gender in polycythemia vera but female gender in essential thrombocythemia. These results suggest that age promotes development or expansion of homozygous-mutant clones and that gender modulates the phenotypic consequences of JAK2V617F homozygosity, thus providing a potential explanation for the long-standing observations of a preponderance of men with polycythemia vera but of women with essential thrombocythemia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23633544      PMCID: PMC3640115          DOI: 10.3324/haematol.2012.079129

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  24 in total

1.  Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

Authors:  Linda M Scott; Mike A Scott; Peter J Campbell; Anthony R Green
Journal:  Blood       Date:  2006-06-13       Impact factor: 22.113

Review 2.  The myeloproliferative disorders.

Authors:  Peter J Campbell; Anthony R Green
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

3.  Age-dependent usage of double-strand-break repair pathways.

Authors:  Christine R Preston; Carlos Flores; William R Engels
Journal:  Curr Biol       Date:  2006-10-24       Impact factor: 10.834

4.  Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area.

Authors:  M K Jensen; P de Nully Brown; O J Nielsen; H C Hasselbalch
Journal:  Eur J Haematol       Date:  2000-08       Impact factor: 2.997

5.  JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

Authors:  Catherine Lacout; Didier F Pisani; Micheline Tulliez; Françoise Moreau Gachelin; William Vainchenker; Jean-Luc Villeval
Journal:  Blood       Date:  2006-05-02       Impact factor: 22.113

6.  A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.

Authors:  F Passamonti; E Rumi; D Pietra; C Elena; E Boveri; L Arcaini; E Roncoroni; C Astori; M Merli; S Boggi; C Pascutto; M Lazzarino; M Cazzola
Journal:  Leukemia       Date:  2010-07-15       Impact factor: 11.528

7.  An age-induced switch to a hyper-recombinational state.

Authors:  Michael A McMurray; Daniel E Gottschling
Journal:  Science       Date:  2003-09-26       Impact factor: 47.728

8.  Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia.

Authors: 
Journal:  Ann Intern Med       Date:  1995-11-01       Impact factor: 25.391

9.  Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.

Authors:  Edwin Chen; Philip A Beer; Anna L Godfrey; Christina A Ortmann; Juan Li; Ana P Costa-Pereira; Catherine E Ingle; Emmanouil T Dermitzakis; Peter J Campbell; Anthony R Green
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

10.  JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.

Authors:  Anna L Godfrey; Edwin Chen; Francesca Pagano; Christina A Ortmann; Yvonne Silber; Beatriz Bellosillo; Paola Guglielmelli; Claire N Harrison; John T Reilly; Frank Stegelmann; Fontanet Bijou; Eric Lippert; Mary F McMullin; Jean-Michel Boiron; Konstanze Döhner; Alessandro M Vannucchi; Carlos Besses; Peter J Campbell; Anthony R Green
Journal:  Blood       Date:  2012-08-16       Impact factor: 22.113

View more
  12 in total

Review 1.  Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions.

Authors:  Jamile M Shammo; Brady L Stein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 2.  SOHO State-of-the-Art Update and Next Questions: MPN.

Authors:  Prithviraj Bose; Jason Gotlib; Claire N Harrison; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-01

3.  Polycythemia vera associated with IgA nephropathy: A case report and literature review.

Authors:  Hong Chen; Baohe Zhang; Mingxu Li; Ruilan Hu; Chunhua Zhou
Journal:  Exp Ther Med       Date:  2015-06-11       Impact factor: 2.447

Review 4.  Molecular classification of myeloproliferative neoplasms-pros and cons.

Authors:  Moosa Qureshi; Claire Harrison
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 5.  Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.

Authors:  Brady L Stein; Stephen T Oh; Dmitriy Berenzon; Gabriela S Hobbs; Marina Kremyanskaya; Raajit K Rampal; Camille N Abboud; Kenneth Adler; Mark L Heaney; Elias J Jabbour; Rami S Komrokji; Alison R Moliterno; Ellen K Ritchie; Lawrence Rice; John Mascarenhas; Ronald Hoffman
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

Review 6.  Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.

Authors:  Jacob Grinfeld; Jyoti Nangalia; Anthony R Green
Journal:  Haematologica       Date:  2016-12-01       Impact factor: 9.941

7.  Nongenetic stochastic expansion of JAK2V617F-homozygous subclones in polycythemia vera?

Authors:  Anna L Godfrey; Jyoti Nangalia; E Joanna Baxter; Charles E Massie; David G Kent; Elli Papaemmanuil; Peter J Campbell; Anthony R Green
Journal:  Blood       Date:  2014-11-20       Impact factor: 22.113

8.  Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia.

Authors:  E K Engle; D A C Fisher; C A Miller; M D McLellan; R S Fulton; D M Moore; R K Wilson; T J Ley; S T Oh
Journal:  Leukemia       Date:  2014-09-25       Impact factor: 11.528

Review 9.  Molecular pathogenesis of the myeloproliferative neoplasms.

Authors:  Graeme Greenfield; Mary Frances McMullin; Ken Mills
Journal:  J Hematol Oncol       Date:  2021-06-30       Impact factor: 17.388

10.  Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.

Authors:  Daniela Barraco; Barbara Mora; Paola Guglielmelli; Elisa Rumi; Margherita Maffioli; Alessandro Rambaldi; Marianna Caramella; Rami Komrokji; Jason Gotlib; Jean Jacques Kiladjian; Francisco Cervantes; Timothy Devos; Francesca Palandri; Valerio De Stefano; Marco Ruggeri; Richard T Silver; Giulia Benevolo; Francesco Albano; Michele Merli; Daniela Pietra; Tiziano Barbui; Giada Rotunno; Mario Cazzola; Toni Giorgino; Alessandro Maria Vannucchi; Francesco Passamonti
Journal:  Blood Cancer J       Date:  2018-09-21       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.